← 返回前沿论文

类特洛伊木马的仿生纳米 NK 诱导免疫刺激性肿瘤微环境以增强 GBM 化疗-免疫治疗

英文原题:A Trojan-Horse-Like Biomimetic Nano-NK to Elicit an Immunostimulatory Tumor Microenvironment for Enhanced GBM Chemo-Immunotherapy.

PubMed 2023/07/07(内容时间) Small Q1 · IF 11.8(JCR 2025)

研究概要

尽管化疗和免疫治疗在包括脑转移在内的多种实体瘤中取得了良好疗效,但它们在胶质母细胞瘤(GBM)中的临床疗效却令人失望。

中文摘要

尽管化疗和免疫治疗对包括脑转移在内的多种实体瘤取得了良好疗效,但其在胶质母细胞瘤(GBM)中的临床疗效令人失望。缺乏安全有效的跨血脑屏障(BBB)递送系统以及免疫抑制性肿瘤微环境(TME)是GBM治疗的两大主要障碍。在此,设计了一种类似特洛伊木马的纳米颗粒系统,其将生物相容性PLGA包覆的替莫唑胺(TMZ)和IL-15纳米颗粒(NPs)封装于cRGD修饰的NK细胞膜内(R-NKm@NP),以激发GBM化学免疫治疗的免疫刺激性TME。借助外层NK细胞膜与cRGD的协同作用,R-NKm@NPs有效穿越BBB并靶向GBM。此外,R-NKm@NPs表现出良好的抗肿瘤能力,并延长了GBM荷瘤小鼠的中位生存期。值得注意的是,R-NKm@NPs治疗后,局部释放的TMZ和IL-15协同刺激NK细胞的增殖和活化,导致树突状细胞成熟和CD8+细胞毒性T细胞浸润,激发免疫刺激性TME。最后,R-NKm@NPs不仅有效延长了药物在体内的代谢循环时间,而且没有明显的副作用。本研究可能为未来开发仿生纳米颗粒以增强GBM化学和免疫治疗提供有价值的见解。

展开英文摘要原文

Although the chemo- and immuno-therapies have obtained good responses for several solid tumors, including those with brain metastasis, their clinical efficacy in glioblastoma (GBM) is disappointing. The lack of safe and effective delivery systems across the blood-brain barrier (BBB) and the immunosuppressive tumor microenvironment (TME) are two main hurdles for GBM therapy. Herein, a Trojan-horse-like nanoparticle system is designed, which encapsulates biocompatible PLGA-coated temozolomide (TMZ) and IL-15 nanoparticles (NPs) with cRGD-decorated NK cell membrane (R-NKm@NP), to elicit the immunostimulatory TME for GBM chemo-immunotherapy. Taking advantage of the outer NK cell membrane cooperating with cRGD, the R-NKm@NPs effectively traversed across the BBB and targeted GBM. In addition, the R-NKm@NPs exhibited good antitumor ability and prolonged the median survival of GBM-bearing mice. Notably, after R-NKm@NPs treatment, the locally released TMZ and IL-15 synergistically stimulated the proliferation and activation of NK cells, leading to the maturation of dendritic cells and infiltration of CD8 + cytotoxic T cells, eliciting an immunostimulatory TME. Lastly, the R-NKm@NPs not only effectively prolonged the metabolic cycling time of the drugs in vivo, but also has no noticeable side effects. This study may offer valuable insights for developing biomimetic nanoparticles to potentiate GBM chemo- and immuno-therapies in the future.

论文信息

作者
Zhang L、Zhang Y、Wang X、Zhou Y、Qi J、Gu L、Zhao Q、Yu R
单位
Institute of Nervous System Diseases, Xuzhou Medical University, Xuzhou, Jiangsu, 221002, China.China
文献类型
非美国政府资助研究
期刊
Small (Weinheim an der Bergstrasse, Germany)2023 Nov
原文标识
PubMed 37420326 · DOI 10.1002/smll.202301439